Literature DB >> 26100596

Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.

Nai-Jung Chiang1, Yan-Shen Shan2, Wen-Chun Hung3, Li-Tzong Chen4.   

Abstract

Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial cells lining the biliary tract. Despite the existence of variation in incidence and etiology worldwide, its incidence is increasing globally in the past few decades. Surgery is the only curative treatment option for a minority of patients presented with early disease; while moderate effective chemotherapy remains the standard care for patients with locally advanced or metastatic diseases. In this article, we briefly review the molecular alterations that have been described in CCAs focusing on the role of epigenetic modification, including promoter methylation inactivation, histone modification and microRNA, in the carcinogenesis and progression of CCAs. This article is part of a Directed Issue entitled: Epigenetics dynamics in development and disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; DNA methylation; Epigenetic regulation; Histone modification; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26100596     DOI: 10.1016/j.biocel.2015.06.012

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  10 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

Review 2.  Molecular profiling of biliary tract cancer: a target rich disease.

Authors:  Apurva Jain; Milind Javle
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 3.  Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

Authors:  Apurva Jain; Lawrence N Kwong; Milind Javle
Journal:  Curr Treat Options Oncol       Date:  2016-11

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

5.  Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression.

Authors:  Cuiping Wu; Jinmei Zhang; Xiangang Cao; Qian Yang; Dequan Xia
Journal:  Med Sci Monit       Date:  2016-07-29

6.  Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.

Authors:  Daniel H Ahn; Hatice Gulcin Ozer; Baris Hancioglu; Gregory B Lesinski; Cynthia Timmers; Tanios Bekaii-Saab
Journal:  Oncotarget       Date:  2016-02-02

7.  The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells.

Authors:  Giovanni Di Maira; Alessandra Gentilini; Mirella Pastore; Alessandra Caligiuri; Benedetta Piombanti; Chiara Raggi; Elisabetta Rovida; Monika Lewinska; Jesper B Andersen; Christian Borgo; Mauro Salvi; Daniele Ottaviani; Maria Ruzzene; Fabio Marra
Journal:  Oncogenesis       Date:  2019-10-22       Impact factor: 7.485

Review 8.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

9.  Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.

Authors:  Li Su; Xinglong Zhang; Lei Zheng; Miaomiao Wang; Zhifa Zhu; Ping Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

10.  The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10.

Authors:  Zhao Liu; Lili Pan; Xiaofang Yan; Xiuna Duan
Journal:  FEBS Open Bio       Date:  2020-12-31       Impact factor: 2.792

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.